ArticleCureus2025
Survival Analysis Using Neoadjuvant Rectal Score in Locally Advanced Rectal Cancer Patients Who Underwent Surgery After Neoadjuvant Chemoradiotherapy: An Ambispective Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose The purpose of this study is to stratify patients into various risk groups based on their neoadjuvant rectal (NAR) score and study the predictive value of the NAR score in terms of oncological outcomes. This, in turn, can be used as a surrogate marker to prognosticate the patients and also to study the efficacy of various neoadjuvant therapeutic options. Methodology This ambispective observational study of patients who underwent long-course neoadjuvant chemoradiotherapy (NACTRT), followed by curative surgery in the form of anterior resection (AR) or abdominoperineal resection (APR), from 2010 to 2015 at a high-volume tertiary cancer center in South Kerala, with the survival data collected prospectively. The clinicopathological details of the patients were obtained. ypTNM status was recorded, and the NAR score was calculated. The patients were prospectively followed up for recurrence or death. All endpoints were calculated from the date of the start of NACTRT. Results Four hundred fifty-nine patients were included in the study, with 190 (41.4%) being women and 202 (44%) being less than 60 years old. Two hundred fourteen (46.62%) had lesions of 5-10 cm from the anal verge. Three hundred fifty-nine (78.21%) patients had T3 disease pre-NACTRT. Two hundred twenty-eight patients (51.85%) had undergone APR, and 369 (80.4%) had open surgery. Fifty-one patients (11.1%) had attained pathological complete response (PCR). One hundred twenty-eight patients (27.8%) had disease recurrence, of which 71 had distant metastasis. NAR was a significant predictor of overall survival (OS), disease-free survival (DFS), distant metastasis-free interval (DMFI), and locoregional relapse-free interval (LRFI). On the multivariate analysis of factors predicting survival, only NAR was found to be significant. Conclusion The NAR score is a significant predictor of OS, DFS, LRFI, and DMFI and can be used as a short-term surrogate for survival data in anticipated trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.